Test ID: VHLKP
Von Hippel-Lindau (VHL) Gene, Known Mutation

Diagnosis of suspected von Hippel-Lindau disease, when familial mutations have been previously identified

Screening presymptomatic members of von Hippel-Lindau families, when familial mutations have been previously identified

Tailoring optimal tumor-surveillance strategies for patients, when used in conjunction with phenotyping, when familial mutations have been previously identified

• Informed Consent for Genetic Testing
• VHL Gene Testing Patient Information Sheet

Polymerase Chain Reaction (PCR) Amplification/DNA Sequencing

(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)

Container/Tube: Lavender top (EDTA)

Specimen Volume: 3 mL

Collection Instructions: Send specimen in original tube.

Additional Information:

1. This test can only be performed if a mutation has previously been identified in a family member of this individual. Documentation of the specific familial mutations must be provided with the specimen in order to perform this test. If the familial mutation is a large or exonic deletion, order VHLD/89211 Von Hippel-Lindau (VHL) Deletion Detection. If a familial mutation has not been previously identified, order VHLSP/89083 Von Hippel-Lindau (VHL) Gene, Full Gene Analysis.

2. Transfusions will interfere with testing for up to 4 to 6 weeks. DNA obtained from white cells may not provide useful information for patients who received a recent transfusion of blood that was not leukocyte-reduced. Wait 4 to 6 weeks until transfused cells have left the patient's circulation before drawing the patient's blood specimen for genotype testing.

Forms:

1. VHL Gene Testing Patient Information Sheet (Supply T641) in Special Instructions is required.

2. Informed Consent for Genetic Testing (Supply T576) in Special Instructions is required.

3. New York Clients-Informed consent is required. Please document on the request form or electronic order that a copy is on file. An Informed Consent for Genetic Testing (Supply T576) is available in Special Instructions.

von Hippel-Lindau (VHL) disease is an autosomal dominant cancer syndrome with a birth incidence of approximately 1:36,000 livebirths. It predisposes affected individuals to the development of mainly 5 different types of neoplasms: retinal angioma (>90% penetrance), cerebellar hemangioblastoma (CHB, >80% penetrance), clear-cell renal cell carcinoma (cRCC, approximately 75% penetrance), spinal hemangioblastoma (SHB, approximately 50% penetrance), and pheochromocytoma (PC, approximately 30% penetrance). Angiomas in other organs, pancreatic cysts/adenomas/carcinomas, islet cell tumors, and endolymphatic sac tumors can also occur, but at much lesser frequencies. VHL-related tumors start presenting at approximately 10 to 15 years of age (retinal angioma might present earlier), except for cRCC, which lags about a decade behind. For each tumor type, the incidence rates rise steadily, albeit at different slopes, throughout life.

VHL disease is caused by germline loss-of-function point mutations, deletions or insertions (approximately 80% of cases), or large germline deletions (approximately 20% of cases) of 1 copy of the VHL gene. Approximately 20% of cases are due to new mutations. VHL codes for a protein that is involved in ubiquitination and degradation of a variety of other proteins, most notably hypoxia-inducible factor (HIF). HIF induces expression of genes that promote cell survival and angiogenesis under conditions of hypoxia. It is believed that diminished HIF degradation due to inactive VHL protein causes the tumors in VHL disease. Tumors form when the remaining intact copy of VHL is somatically inactivated in target tissues. Sporadic cRCC, unrelated to VHL disease, also shows somatic deletions, mutations, or aberrant methylation in 80% to 100% of cases.

Retinal angioma, CHB, and SHB cause morbidity, and some mortality, through pressure on adjacent structures and through retinal or subarachnoid hemorrhages. VHL-related cRCC and PC follow a similar clinical course as their sporadic counterparts, with substantial morbidity and mortality. Early detection of VHL-related tumors can reduce these adverse outcomes, and surveillance of affected individuals is therefore widely advocated. Genetic testing is the most accurate way to identify presymptomatic individuals, who can then be entered into a surveillance program.

Genetic testing might also predict the types of tumors that will occur, and can, therefore, be used to individualize surveillance programs. Certain combinations of the 5 major VHL-tumors cluster in VHL families. This observation has led to a phenotype-based classification of VHL syndrome into type 1 (cRCC with any combination of retinal angioma, CHB, or SHB), type 2A (PC with any combination of retinal angioma, CHB, or SHB), type 2B (both cRCC and PC with any combination of retinal angioma, CHB, or SHB) and type 2C (isolated PC). Type 1 accounts for 60% to 80% of cases, while type 2C is exceedingly rare. However, phenotyping is only accurate in large kindreds. In smaller kindreds, genetic testing can assist in tailoring follow-up to patient needs. For example, missense mutations, particularly those affecting surface amino acids involved in maintaining the surface structural integrity of VHL protein, are strongly associated with PC. By contrast, nonsense or frameshift mutations that disrupt overall VHL protein structure and large deletions are associated with early clinical presentation and increased age-related risks for retinal angioma and cRCC.

An interpretive report will be provided.

All detected alterations will be evaluated according to American College of Medical Genetics and Genomics (ACMG) recommendations.(1) Variants will be classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.

Rarely, unknown polymorphisms in primer- or probe-binding sites can result in false-negative test results (DNA sequencing) due to selective allelic drop-out.

If the specimen is from a tumor (frozen tissue), in particular a sporadic tumor (rather than a von Hippel-Lindau-related tumor), 1 of the alleles might be inactivated by promoter hypermethylation. Our assay does not detect hypermethylation.

The identification of a disease-causing mutation in an affected family member is necessary before predictive testing for other family members can be offered. If a familial mutation has not been previously identified, order VHLSP/89083 von Hippel-Lindau (VHL) Gene, Full Gene Analysis.

Analysis is performed for the familial mutation(s) provided only. This assay does not rule out the presence of other mutations within this gene or within other genes that may be associated with von Hippel-Lindau.

Test results should be interpreted in the context of clinical findings, family history, and other laboratory data. Any error in the diagnosis or in the pedigree provided to us, including false-paternity, could lead to erroneous interpretation of results.

Accuracy was assessed by sequencing 25 specimens from patients with clear-cell renal cell carcinoma (cRCC) of which 6 (24%) showed mutations. These results are in agreement with published estimates of mutation rates of 29% to 61% for von Hippel-Lindau in cRCC. Additionally, 2 specimens with known mutations were tested. Sequences were 100% concordant with published data. Both inter- and intra-assay testing showed 100% consistency in sequencing. Fifteen normal specimens tested; all showed 100% normal sequences.

1. Richards CS et al: ACMG Recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007. Genet Med 2008:10[4]:294-300

2. Online Mendelian inheritance in Man-OMIM: http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=193300

3. Universal Mutation database-UMD-VHL mutations database page: http://www.umd.be:2020/

4. Maher ER, Kaelin WG Jr: von Hippel-Lindau disease (Reviews in Molecular Medicine). Medicine 1997;76:381-391

5. Pack SD, Zbar B, Pak E, et al: Constitutional von Hippel-Lindau (VHL) gene deletions detected in VHL families by fluorescence in situ hybridization. Cancer Res 1999;59:5560-5564

6. Richards FM: Molecular pathology of von Hippel-Lindau disease and the VHL tumor suppressor gene. Expert Rev Mol Med 2001;3:1-27

7. Hes FJ, Hoppener JWM, Lips CJM: Clinical review 155: pheochromocytoma in von Hippel-Lindau disease. J Clin Endocrinol Metab 2003;88:969-974

8. Ong KR, Woodward ER, Killick P, et al: Genotype-phenotype correlations in von Hippel-Lindau disease. Hum Mutat 2007;28:143-149

Fluorescent DNA sequence analysis is performed to test for the presence of a specific von Hipple Lindau (VHL) mutation previously identified in an affected family member(GenBank accession number: NM_000551.2).(Unpublished Mayo method)

Monday; 8 am

81403-Known familial variant, not otherwise specified, for gene listed in Tier 1 or Tier 2, DNA sequence analysis